Ipamorelin (5mg x 10 Vials) + Mod GRF 1 29 (CJC 1295 no DAC) (5mg x 10 Vials)
Misc (Generics)
Research PeptidesGrowth Hormone Releasing Peptide Blend
Certifications
- Marketed as a laboratory research reagent only; not authorised as a medicinal product or medical device.
- End user is responsible for ensuring use complies with local research, safety and import regulations.
- Marketed as a laboratory research reagent only; not authorised as a medicinal product or medical device.
- End user is responsible for ensuring use complies with local research, safety and import regulations.
Growth Hormone Releasing Peptide Blend
Description
Combination research peptide package containing two separate lyophilised peptide preparations: Ipamorelin (5 mg per vial, 10 vials) and Mod GRF 1-29, also known as CJC-1295 without DAC (5 mg per vial, 10 vials). Both peptides are supplied as sterile lyophilised powders intended exclusively for laboratory research use (e.g. in vitro or in vivo experimental models) and are not approved medicines or dietary supplements. Ipamorelin is a growth hormone secretagogue receptor (GHS-R/ghrelin receptor) agonist pentapeptide, while Mod GRF 1-29 is a tetrasubstituted analogue of growth hormone-releasing hormone (GHRH), often studied in combination due to potential synergistic effects on growth hormone secretion in research settings.
Bnefits
- Includes two complementary research peptides in one package: Ipamorelin and Mod GRF 1-29 (CJC-1295 no DAC)
- Each peptide supplied as 5 mg lyophilised powder in 10 separate vials for flexible dosing in laboratory protocols
- Ipamorelin is a selective growth hormone secretagogue receptor (ghrelin receptor) agonist pentapeptide used in experimental GH-release models
- Mod GRF 1-29 (tetrasubstituted GHRH analogue) is studied for increased stability and prolonged activity versus native GRF 1-29
- Combination commonly investigated for potentially synergistic effects on pulsatile growth hormone release in research models
- Lyophilised form helps support peptide stability during shipping and storage when handled correctly
- Clearly labelled and packaged for professional laboratory handling; not presented or authorised as a medicinal product
Indications
- Laboratory research use only (e.g. in vitro assays or approved in vivo experimental models investigating growth hormone–related pathways)
- Experimental study of growth hormone secretagogue receptor (GHS-R) ligands (Ipamorelin) and GHRH analogues (Mod GRF 1-29/CJC-1295 no DAC)
- Research on potential synergistic effects of combined GHRH analogues and GHS-R agonists on growth hormone secretion and related signalling
- Educational, analytical or reference use in controlled laboratory environments by qualified personnel
Composition
- Ipamorelin: 5 mg lyophilised peptide powder per vial (10 vials)
- Mod GRF 1-29 (CJC-1295 no DAC): 5 mg lyophilised peptide powder per vial (10 vials)
- Excipients: not fully specified; typically includes buffering agents and stabilisers appropriate for lyophilised peptides
Formulation
- Sterile lyophilised (freeze-dried) peptide powders in glass vials
- Ipamorelin peptide (sequence commonly given in literature as Aib-His-D-2-Nal-D-Phe-Lys-NH2)
- Mod GRF 1-29 peptide (tetrasubstituted GHRH analogue corresponding to a 29–amino acid fragment of GHRH with four stabilising substitutions)
- Supplied without diluent; reconstitution with a suitable solvent (e.g. bacteriostatic water) is required for experimental use
Packaging
- 10 x 5 mg vials of Ipamorelin lyophilised peptide
- 10 x 5 mg vials of Mod GRF 1-29 (CJC-1295 no DAC) lyophilised peptide
- Total 20 vials per combination package
- Packaged for shipment at controlled temperatures as a research reagent
Usage
- For laboratory research use only; not for human or veterinary use, diagnostic use, or consumption.
- Handle only by qualified professionals in an appropriate laboratory environment, following institutional biosafety and chemical handling procedures.
- On receipt, inspect vials for integrity of seals and absence of visible contamination or damage before use.
- Reconstitute each vial with a suitable sterile solvent (e.g. bacteriostatic or sterile water for injection) in a clean environment according to internal laboratory SOPs; record reconstitution volume and resulting concentration.
- Avoid repeated freeze–thaw cycles of reconstituted solutions; prepare aliquots where appropriate to maintain peptide stability.
- Label all reconstituted solutions clearly with peptide name, concentration, date of reconstitution and storage conditions.
- Dispose of all unused material, vials, syringes and consumables as laboratory chemical/biological waste in accordance with local regulations.
- Do not use this product as a drug, cosmetic or dietary supplement, and do not administer to humans or animals.
Contraindications
- Not for human or veterinary use, injection or consumption under any circumstances.
- Should not be handled by untrained personnel or used outside appropriately equipped laboratory or research facilities.
- Avoid use in open environments where aerosolisation or accidental exposure is possible; handle within appropriate containment as required by local regulations.
- Avoid handling during pregnancy or breastfeeding; minimise direct contact with skin, eyes and mucous membranes.
Adverse Effects
- No safety profile established for human or veterinary use as this is a research-only product.
- Potential risks include unknown toxicological, allergenic, reproductive or carcinogenic effects if mishandled or misused.
- Laboratory personnel may experience irritation or sensitisation on contact; appropriate PPE (gloves, coat, eye protection) should be worn.
- Accidental exposure (e.g. skin contact, inhalation, eye contact) should be managed according to institutional chemical/biological exposure procedures.
Storage Conditions
- Keep vials tightly closed in their original packaging until use.
- Store lyophilised peptide in a cool, dry, dark place; refrigeration (approximately 2–8°C) is typically recommended for short- to medium-term storage.
- For long-term storage, freezing at lower temperatures (e.g. ≤ -20°C) is generally recommended for lyophilised peptides, following institutional guidelines.
- Protect from direct light, moisture and excessive heat.
- After reconstitution, store solutions at refrigerated temperatures and use within timeframes defined by internal laboratory stability protocols; avoid repeated freeze–thaw cycles.
- Keep out of reach of unauthorised personnel and children.
Duration
Not applicable \u2013 this is a research-use-only peptide product with no authorised therapeutic regimen or treatment duration.
Onset
Not applicable \u2013 pharmacodynamic onset and clinical effects in humans are not established; product is not approved for therapeutic use.
